Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15(3):172–84. https://doi.org/10.1038/nri3814.

Article  CAS  PubMed  Google Scholar 

Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the international lymphoma epidemiology consortium (InterLymph). Blood. 2007;110(2):695–708. https://doi.org/10.1182/blood-2006-11-051672.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mlynarczyk C, Fontán L, Melnick A. Germinal center-derived lymphomas: the darkest side of humoral immunity. Immunol Rev. 2019;288(1):214–39. https://doi.org/10.1111/imr.12755.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-hodgkin lymphoma. BMJ. 2018;362:k3204. https://doi.org/10.1136/bmj.k3204.

Article  PubMed  Google Scholar 

Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84(1):1–12. https://doi.org/10.1007/s00277-004-0939-7.

Article  PubMed  Google Scholar 

Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica. 2016;101(10):1244–50. https://doi.org/10.3324/haematol.

Article  PubMed  PubMed Central  Google Scholar 

Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494–506. https://doi.org/10.3324/haematol.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lue JK, O’Connor OA. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. Lancet Haematol. 2020;7(11):e838–50. https://doi.org/10.1016/S2352-3026(20)30222-2.

Article  PubMed  Google Scholar 

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106(12):3725–32. https://doi.org/10.1182/blood-2005-01-0016.

Article  CAS  PubMed  Google Scholar 

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8. https://doi.org/10.1182/blood-2017-03-769620.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–65. https://doi.org/10.1200/JCO.19.00172.

Article  CAS  PubMed  Google Scholar 

Alonso-Álvarez S, Manni M, Montoto S, Sarkozy C, Morschhauser F, Wondergem MJ, et al. Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. Eur J Cancer. 2021;157:132–9. https://doi.org/10.1016/j.ejca.2021.08.005.

Article  PubMed  Google Scholar 

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. https://doi.org/10.1016/S0140-6736(12)61763-2.

Article  CAS  PubMed  Google Scholar 

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–26. https://doi.org/10.1016/S0140-6736(13)60313-X.

Article  CAS  PubMed  Google Scholar 

Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295–308. https://doi.org/10.1016/S2352-3026(20)30031-4.

Article  PubMed  Google Scholar 

Ekberg S, Harrysson S, Jernberg T, Szummer K, Andersson PO, Jerkeman M, et al. Myocardial infarction in diffuse large B-cell lymphoma patients—a population-based matched cohort study. J Intern Med. 2021;290(5):1048–60. https://doi.org/10.1111/joim.13303.

Article  CAS  PubMed  Google Scholar 

Manson G, Houot R. Next-generation immunotherapies for lymphoma: one foot in the future. Ann Oncol. 2018;29(3):588–601. https://doi.org/10.1093/annonc/mdy032.

Article  CAS  PubMed  Google Scholar 

Ansell SM, Lin Y. Immunotherapy of lymphomas. J Clin Invest. 2020;130(4):1576–85. https://doi.org/10.1172/JCI129206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, et al. Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin. J Clin Oncol. 2021;39(9):1001–9. https://doi.org/10.1200/JCO.20.01691.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–11. https://doi.org/10.1200/JCO.2014.59.5363.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westin J. Ibrutinib and lenalidomide: when 1+1 = >2. Blood. 2019;134(13):996–8. https://doi.org/10.1182/blood.2019002237.

Article  CAS  PubMed  Google Scholar 

Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, et al. Long-term follow-up and correlative analysis of two phase II trials of rituximab and lenalidomide followed by continuous lenalidomide in untreated and relapsed/refractory indolent lymphoma. Clin Cancer Res. 2021;27(17):4726–36. https://doi.org/10.1158/1078-0432.CCR-20-4622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aiman W, Ali MA, Ali R, Fatima FN, Mirza N, Javaid A, et al. Efficacy and safety of lenalidomide based regimens in diffuse large B cell lymphoma: a systematic review and meta-analysis of clinical trials. Blood. 2020;136(Supplement 1):13–4. https://doi.org/10.1182/blood-2020-136017.

Article  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.

Article  PubMed  Google Scholar 

Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD anderson cancer center in the rituximab era. Ann Oncol. 2016;27(5):895–901. https://doi.org/10.1093/annonc/mdw026.

Article  CAS  PubMed  Google Scholar 

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. 2019;134(4):353–62. https://doi.org/10.1182/blood-2018-10-879643.

Article  CAS  PubMed  Google Scholar 

Ayers EC, Margolis D, Landsburg DJ. Real world outcomes in patients with relapsed/refractory diffuse large b-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk. 2020;20(10):661–7. https://doi.org/10.1016/j.clml.2020.05.008.

Article  PubMed  PubMed Central  Google Scholar 

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–47. https://doi.org/10.1056/NEJMoa1805104.

Article  CAS  PubMed  Google Scholar 

Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329–38. https://doi.org/10.1200/JCO.20.01375.

Article  CAS  PubMed  PubMed Central  Google Scholar